Bromodomains: a new target class for drug development
Top Cited Papers
- 4 July 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 18 (8), 609-628
- https://doi.org/10.1038/s41573-019-0030-7
Abstract
Less than a decade ago, it was shown that bromodomains, acetyl lysine ‘reader’ modules found in proteins with varied functions, were highly tractable small-molecule targets. This is an unusual property for protein–protein or protein–peptide interaction domains, and it prompted a wave of chemical probe discovery to understand the biological potential of new agents that targeted bromodomains. The original examples, inhibitors of the bromodomain and extra-terminal (BET) class of bromodomains, showed enticing anti-inflammatory and anticancer activities, and several compounds have since advanced to human clinical trials. Here, we review the current state of BET inhibitor biology in relation to clinical development, and we discuss the next wave of bromodomain inhibitors with clinical potential in oncology and non-oncology indications. The lessons learned from BET inhibitor programmes should affect efforts to develop drugs that target non-BET bromodomains and other epigenetic readers.This publication has 261 references indexed in Scilit:
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancyNature Genetics, 2013
- Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding SitesJournal of Medicinal Chemistry, 2012
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- A Poised Chromatin Platform for TGF-β Access to Master RegulatorsCell, 2011
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- TRIM24 links a non-canonical histone signature to breast cancerNature, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005